Ameriprise’s Tenaya Therapeutics TNYA Stock Holding History

Ameriprise’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,545	Closed	-$61.9K	–	3974
2023 Q2	$61.9K	Buy	+10,545	New	+$61.3K	﹤0.01%	3856

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Ameriprise's TNYA Position: Q3 2023 in Review

Ameriprise sold out of Tenaya Therapeutics (TNYA) in Q3 2023, closing a stake of 10,545 shares — an estimated $61.9K sold.

Ameriprise first reported a position in TNYA in Q2 2023 and held it in 1 quarter. The position peaked at $61.9K in Q2 2023. 76 funds tracked by Wall St. Rank hold TNYA as of Q3 2023.

Ameriprise reported no remaining Tenaya Therapeutics position as of Q3 2023 after selling out during the quarter.
Ameriprise sold 10,545 Tenaya Therapeutics shares in Q3 2023, an estimated $61.9K.
Ameriprise first reported a position in Tenaya Therapeutics in Q2 2023 and held it in 1 quarter.
Ameriprise's Tenaya Therapeutics position peaked at $61.9K in Q2 2023.
76 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2023.

Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.